BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company's pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient's own somatic or adult stem cells, at the desired location.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NYSEMKT
- Symbol: BTX
- CUSIP: 09066L10
Companies Related to BioTime:
- Previous Close: $2.97
- 50 Day Moving Average: $3.23
- 200 Day Moving Average: $3.37
- 52-Week Range: $2.15 - $4.01
- Trailing P/E Ratio: 12.09
- Foreward P/E Ratio: -7.76
- P/E Growth: 0.00
- Market Cap: $326.81M
- Outstanding Shares: 102,772,000
- Beta: 1.37
What is BioTime's stock symbol?
BioTime trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "BTX."
Where is BioTime's stock going? Where will BioTime's stock price be in 2017?
3 brokers have issued 12-month target prices for BioTime's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate BioTime's stock price to reach $6.00 in the next twelve months.
When will BioTime announce their earnings?
BioTime is scheduled to release their next quarterly earnings announcement on Thursday, March, 9th 2017.
Who owns BioTime stock?
BioTime's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.02%), Two Sigma Investments LP (0.06%), Metropolitan Life Insurance Co. NY (0.05%), Intellectus Partners LLC (0.03%) and Guggenheim Capital LLC (0.03%). Company insiders that own BioTime stock include Alfred D Kingsley, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Stephen C Farrell and Stephen Lahue Cartt.
Who sold BioTime stock? Who is selling BioTime stock?
BioTime's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY.
Who bought BioTime stock? Who is buying BioTime stock?
BioTime's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Intellectus Partners LLC, Two Sigma Investments LP and Guggenheim Capital LLC. Company insiders that have bought BioTime stock in the last two years include Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Stephen C Farrell and Stephen Lahue Cartt.
How do I buy BioTime stock?
Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BioTime stock cost?
One share of BioTime stock can currently be purchased for approximately $3.18.